Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
What dose would you use to treat?
Related Questions
What ipsilateral lung constraints if any do you utilize for SBRT and or hypofractionated RT in the lungs?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
For ultracentral lung cancer abutting the heart, what dose constraints would you use for the heart and bronchus if using 10 fraction ultrahypofractionation?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
How do you define treatment volumes for patients treated with neoadjuvant chemoimmunotherapy for resectable NSCLC who are no longer surgical candidates or decline surgery?
How would you post-operatively manage a peripheral stage I small cell lung carcinoma s/p upfront wedge resection with an R1 microscopic positive margin along the staple line and visceral pleural invasion?
How do you approach treatment planning for lung SBRT in a patient with a lesion within 1 cm of a defibrillator?
Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?
Would you offer empiric radiation for a growing mediastinal mass radiographically suspicious for thymoma in a patient who declines surgery?